Ginkgo Bioworks Holdings (DNA) Change in Accured Expenses (2020 - 2026)

Ginkgo Bioworks Holdings' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$11.6 million for Q1 2026.

• Quarterly Change in Accured Expenses fell 230.8% year-over-year to -$11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.1 million (up 76.22% YoY) and the FY2025 annual result came in at $10.4 million, up 125.66% from the prior year.
• Change in Accured Expenses was -$11.6 million for Q1 2026 at Ginkgo Bioworks Holdings, down from -$6.6 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $22.1 million in Q3 2025 and bottomed at -$42.0 million in Q3 2024.
• A 5-year average of -$3.8 million and a median of -$818000.0 in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 178.17% — and 2025, when it sank 199814.29%.
• Ginkgo Bioworks Holdings' Change in Accured Expenses stood at -$27.8 million in 2022, then soared by 178.17% to $21.7 million in 2023, then tumbled by 143.0% to -$9.3 million in 2024, then advanced by 29.17% to -$6.6 million in 2025, then plunged by 75.37% to -$11.6 million in 2026.
• Business Quant data shows DNA's Change in Accured Expenses at -$11.6 million in Q1 2026, -$6.6 million in Q4 2025, and $22.1 million in Q3 2025.